Higher-Dose DHA Supplementation Modulates Immune Responses in Pregnancy and Is Associated with Decreased Preterm Birth
Authors:
- Christina J. ValentineCVChristina J. Valentine
- Aiman Q. KhanAKAiman Q. Khan
- Alexandra R. BrownABAlexandra R. Brown
- Scott A. SandsSSScott A. Sands
- Emily A. DefrancoEDEmily A. Defranco
- Byron J. GajewskiBGByron J. Gajewski
- Susan E. CarlsonSCSusan E. Carlson
- Kristina M. ReberKRKristina M. Reber
- Lynette K. RogersLRLynette K. Rogers
Open Access
- 26 November 2021
- Vol. 13 (12) , 4248
Abstract
Pregnancy and parturition involve extensive changes in the maternal immune system. In our randomized, multi-site, double-blind superiority trial using a Bayesian adaptive design, we demonstrated that 1000 mg/day of docosahexaenoic acid (DHA) was superior to 200 mg/day in preventing both early preterm birth (less than 34 weeks’ gestation) and preterm birth (less than 37 weeks’ gestation). The goal of this secondary study is to compare the effects of 1000 mg/day versus 200 mg/day on maternal inflammation, a possible mechanism by which DHA may prevent preterm birth. Maternal blood samples were collected at enrollment (12–20 weeks’ gestation) and at delivery. Red blood cell DHA levels were measured by gas chromatography, and plasma concentrations of sRAGE, IL-6, IL-1β, TNFα, and INFγ were measured by ELISA. Data were analyzed for associations with the DHA dose, gestational age at birth, and preterm birth (<37 weeks). Higher baseline and lower delivery levels of maternal sRAGE were associated with a greater probability of longer gestation and delivery at term gestation. Higher-dose DHA supplementation increased the probability of a smaller decrease in delivery sRAGE levels. Higher IL-6 concentrations at delivery were associated with the probability of delivering after 37 weeks, and higher-dose DHA supplementation increased the probability of greater increases in IL-6 concentrations between enrollment and delivery. These data provide a proposed mechanistic explanation of how a higher dose of DHA during pregnancy provides immunomodulatory regulation in the initiation of parturition by influencing sRAGE and IL-6 levels, which may explain its ability to reduce the risk of preterm birth.Keywords
Funding Information
- National Institute of Child Health and Human Development (R01HD083292)
- Nationwide Children's Hospital (51139-0002-0320)
This publication has 43 references indexed in Scilit:
- Activation of the Receptor for Advanced Glycation End Products System in Women with Severe PreeclampsiaThe Journal of Clinical Endocrinology & Metabolism, 2011
- Docosahexaenoic Acid Improves the Nitroso-Redox Balance and Reduces VEGF-Mediated Angiogenic Signaling in Microvascular Endothelial CellsInvestigative Ophthalmology & Visual Science, 2010
- sRAGE Induces Human Monocyte Survival and DifferentiationThe Journal of Immunology, 2010
- The Receptor for Advanced Glycation End Products (RAGE) and the LungJournal of Biomedicine and Biotechnology, 2010
- Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetesAtherosclerosis, 2009
- The relationship between the fatty acid composition of immune cells and their functionProstaglandins, Leukotrienes and Essential Fatty Acids, 2008
- A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)The FASEB Journal, 2008
- Detection of feto-maternal infection/inflammation by the soluble receptor for advanced glycation end products (sRAGE): results of a pilot studyJournal of Perinatal Medicine, 2008
- Gamma-Tocopherol and Docosahexaenoic Acid Decrease Inflammation in Dialysis PatientsJournal of Renal Nutrition, 2007
- The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease?Laboratory Investigation, 2006